Enterprise Value
697M
Cash
250.9M
Avg Qtr Burn
-83.77M
Short % of Float
18.46%
Insider Ownership
0.33%
Institutional Own.
91.41%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PDUFA Approval decision | ||
Iovance TIL (LN-145) Details Non-small cell lung carcinoma, Cancer | Phase 2 Data readout | |
Iovance TIL (LN-145) mono/combo w/ pembrolizumab Details Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Lifileucel Details Cancer, Cervical cancer | Phase 2 Update | |
IOV-4001 Details Non-small cell lung carcinoma, Cancer, Melanoma | Phase 1/2 Update |